G protein-coupled receptor

μ-opioid receptor

Mu opioid receptor

Opioids act through three classes of receptors, μ, δ and κ. The μ-opioid receptor is the molecular target of morphine in the living animal, and morphine does not act without it.1 Opiates were shown to bind to membrane receptors in the brain in 1973, and the binding sites were named mu, delta and kappa a few years later. The first opioid receptor gene was isolated by expression cloning in 1992, and because of strong sequence homology the whole gene family was cloned within the following two years. Opioid receptors are Gi/o-coupled G protein-coupled receptors.2,3 A review of the last 35 years describes how the picture of the morphine-like drugs and their receptors changed. Early pharmacological studies identified three major classes of receptors, helped by the discovery of the endogenous opioid peptides. Molecular biology then revealed a complexity that had not been appreciated before. The idea of multiple opioid receptors was first suggested almost 50 years before the review.4

In the rat brain, cells with mu receptor mRNA are found in the olfactory bulb, caudate-putamen, nucleus accumbens, septum, most thalamic nuclei, hippocampus and amygdala, and also in the central gray, the raphe nuclei, the locus coeruleus, the nucleus of the solitary tract, the spinal cord and the dorsal root ganglia. Autoradiography found dense mu binding in the anterior cingulate cortex, neocortex, amygdala, hippocampus, nucleus accumbens, caudate putamen, thalamus, habenula, interpeduncular nucleus, the pars compacta of the substantia nigra, the colliculi and the raphe nuclei. Each of the three receptor mRNAs had its own distribution, which agreed well with the known binding.5,6

Opioid receptors regulate pain, reward, mood, stress, gastrointestinal transport and respiration. Agonists can stabilise different active states of a receptor, which is called ligand-directed signalling or biased agonism. For the mu and delta receptors, most of the reported ligand-selective behavioural effects are seen as differences in the adaptation to repeated drug administration.3

In mice without the receptor, morphine relieves no pain, causes no place preference and produces no physical dependence.1 In such mice, a high dose of morphine also no longer reduced breathing, while it did in normal mice.7 In patients, opioid pain treatment is generally safe, with 0.5 percent or less of events from respiratory depression, but fatalities are regularly reported. The only treatment available to reverse the depression is naloxone. Opioids with a high receptor affinity need larger naloxone concentrations or a continuous infusion before the reversal sets in. Experimental approaches to prevent the depression without affecting analgesia include serotonin agonists, ampakines and the antibiotic minocycline.8

Sources (8)
  1. Matthes et al. 1996Matthes HW, Maldonado R, Simonin F, et al. (1996) Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene Nature
  2. Kieffer et al. 2009Kieffer BL, Evans CJ (2009) Opioid receptors: from binding sites to visible molecules in vivo Neuropharmacology
  3. Pradhan et al. 2012Pradhan AA, Smith ML, Kieffer BL, et al. (2012) Ligand-directed signalling within the opioid receptor family Br J Pharmacol
  4. Pasternak et al. 2013Pasternak GW, Pan YX (2013) Mu opioids and their receptors: evolution of a concept Pharmacol Rev
  5. Mansour et al. 1994Mansour A, Fox CA, Burke S, et al. (1994) Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: an in situ hybridization study J Comp Neurol
  6. Mansour et al. 1987Mansour A, Khachaturian H, Lewis ME, et al. (1987) Autoradiographic differentiation of mu, delta, and kappa opioid receptors in the rat forebrain and midbrain J Neurosci
  7. Dahan et al. 2001Dahan A, Sarton E, Teppema L, et al. (2001) Anesthetic potency and influence of morphine and sevoflurane on respiration in mu-opioid receptor knockout mice Anesthesiology
  8. Dahan et al. 2010Dahan A, Aarts L, Smith TW (2010) Incidence, Reversal, and Prevention of Opioid-induced Respiratory Depression Anesthesiology

Binding affinity (Kᵢ)

16 substances, 28 displayed values. Strongest first within each organism. The bar is pKᵢ on a log scale. Open a row to see the assay and every report behind the value.

Human

14 measurements
  • BuprenorphineAgonistunresolved0.22 nMVolpe et al. 2011 · 3 reports
    Assay
    recombinant human MOR (ChemScreen membrane), [3H]DAMGO competition
    Shown value from
    Volpe et al. 2011, Table 2
    Range
    0.22–1.5 nM in 3 reports

    Reported values disagree and no value is established. 3 reports in all, 0.22–1.5 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Volpe et al. 20110.22 nMTable 2
    Toll et al. 19981.5 nMTable 5
    Obeng et al. 20210.90 nMTable 2
  • HydromorphoneAgonist0.37 nMVolpe et al. 2011 · 2 reports
    Assay
    recombinant human MOR (ChemScreen membrane), [3H]DAMGO competition
    Shown value from
    Volpe et al. 2011, Table 2
    Range
    0.28–0.37 nM in 2 reports
    Sources and values behind the range, same assay family
    ReportValueWhere
    Volpe et al. 20110.37 nMTable 2
    Wentland et al. 20090.28 nMTable 1
  • OxymorphoneAgonist0.41 nMVolpe et al. 2011
    Assay
    recombinant human MOR (ChemScreen membrane), [3H]DAMGO competition
    Shown value from
    Volpe et al. 2011, Table 2
  • MorphineAgonistother reports differ1.2 nMVolpe et al. 2011 · 6 reports
    Assay
    recombinant human MOR (ChemScreen membrane), [3H]DAMGO competition
    Shown value from
    Volpe et al. 2011, Table 2
    Range
    0.62–415 nM in 6 reports

    This is the best-supported value. Other reports differ. 7 reports in all, 0.62–415 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Volpe et al. 20111.2 nMTable 2
    Neumeyer et al. 20120.88 nMTable 2
    Gillen et al. 20000.62 nM, 415 nMTable 1, Table 2
    Toll et al. 19981.1 nMTable 5
    Obeng et al. 20214.2 nMTable 2
  • FentanylAgonistunresolved1.3 nMVolpe et al. 2011 · 4 reports
    Assay
    recombinant human MOR (ChemScreen membrane), [3H]DAMGO competition
    Shown value from
    Volpe et al. 2011, Table 2
    Range
    0.70–355 nM in 4 reports

    Reported values disagree and no value is established. 4 reports in all, 0.70–355 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Volpe et al. 20111.3 nMTable 2
    Gillen et al. 2000355 nMTable 2
    Toll et al. 19980.70 nMTable 5
    Obeng et al. 20218.0 nMTable 2
  • MethadoneAgonistunresolved3.4 nMVolpe et al. 2011 · 2 reports
    Assay
    recombinant human MOR (ChemScreen membrane), [3H]DAMGO competition
    Shown value from
    Volpe et al. 2011, Table 2
    Range
    0.60–3.4 nM in 2 reports

    Reported values disagree and no value is established. 2 reports in all, 0.60–3.4 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Volpe et al. 20113.4 nMTable 2
    Toll et al. 19980.60 nMTable 5
  • OxycodoneAgonist16 nMLalovic et al. 2006 · 2 reports
    Assay
    human MOR1 membranes from stably transfected cells, [3H]diprenorphine displacement
    Shown value from
    Lalovic et al. 2006, Table I
    Range
    16–26 nM in 2 reports
    Error
    ± 2.9 SD, n = 2
    Sources and values behind the range, same assay family
    ReportValueWhere
    Volpe et al. 201126 nMTable 2
    Lalovic et al. 200616 nMTable I
  • HydrocodoneAgonistunresolved42 nMVolpe et al. 2011 · 2 reports
    Assay
    recombinant human MOR (ChemScreen membrane), [3H]DAMGO competition
    Shown value from
    Volpe et al. 2011, Table 2
    Range
    9.5–42 nM in 2 reports

    Reported values disagree and no value is established. 2 reports in all, 9.5–42 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Volpe et al. 201142 nMTable 2
    Neumeyer et al. 20129.5 nMTable 2
  • 7-HydroxymitragynineAgonist47 nMKruegel et al. 2016 · 2 reports
    Assay
    cells expressing human MOR, opioid receptor binding
    Shown value from
    Kruegel et al. 2016, Table 2
    Range
    47–78 nM in 2 reports
    Error
    ± 18 SEM
    Sources and values behind the range, same assay family
    ReportValueWhere
    Obeng et al. 202178 nMTable 2
    Kruegel et al. 201647 nMTable 2
  • TapentadolAgonistrange incl. untraced160 nMTzschentke et al. 2007 · 2 reports
    Assay
    human recombinant MOR, [3H]naloxone-type competition (Fig. 2A)
    Shown value from
    Tzschentke et al. 2007, Results text (Fig. 2A)
    Sources and values behind the range, same assay family
    ReportValueWhere
    Tzschentke et al. 2007160 nMResults text (Fig. 2A)
    Roulet et al. 2021160 nMTable 1
  • Mitragynineunresolved233 nMKruegel et al. 2016 · 2 reports
    Assay
    cells expressing human MOR, opioid receptor binding
    Shown value from
    Kruegel et al. 2016, Table 2
    Range
    233–709 nM in 2 reports
    Error
    ± 48 SEM

    Reported values disagree and no value is established. 2 reports in all, 233–709 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Obeng et al. 2021709 nMTable 2
    Kruegel et al. 2016233 nMTable 2
  • PethidineAgonist450 nMVolpe et al. 2011
    Assay
    recombinant human MOR (ChemScreen membrane), [3H]DAMGO competition
    Shown value from
    Volpe et al. 2011, Table 2
  • CodeineAgonistunresolved734 nMVolpe et al. 2011 · 2 reports
    Assay
    recombinant human MOR (ChemScreen membrane), [3H]DAMGO competition
    Shown value from
    Volpe et al. 2011, Table 2
    Range
    135–734 nM in 2 reports

    Reported values disagree and no value is established. 2 reports in all, 135–734 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Volpe et al. 2011734 nMTable 2
    Toll et al. 1998135 nMTable 5
  • Tramadolrange incl. untraced2400 nMGillen et al. 2000 · 2 reports
    Assay
    cloned human MOR in CHO membranes, [3H]naloxone competition, low-salt conditions
    Shown value from
    Gillen et al. 2000, Table 1
    Error
    ± 1100 SD
    Sources and values behind the range, same assay family
    ReportValueWhere
    Gillen et al. 20002400 nMTable 1
    Roulet et al. 20212400 nMTable 1

Guinea pig

5 measurements
  • FentanylAgonist1.0 nMToll et al. 1998
    Assay
    guinea-pig brain membranes, [3H]DAMGO competition
    Shown value from
    Toll et al. 1998, Table 5
    Error
    ± 0.10 SD
  • BuprenorphineAgonist1.3 nMToll et al. 1998
    Assay
    guinea-pig brain membranes, [3H]DAMGO competition
    Shown value from
    Toll et al. 1998, Table 5
    Error
    ± 0.15 SD
  • MethadoneAgonist1.4 nMToll et al. 1998
    Assay
    guinea-pig brain membranes, [3H]DAMGO competition
    Shown value from
    Toll et al. 1998, Table 5
    Error
    ± 0.05 SD
  • MorphineAgonist2.0 nMToll et al. 1998
    Assay
    guinea-pig brain membranes, [3H]DAMGO competition
    Shown value from
    Toll et al. 1998, Table 5
    Error
    ± 0.30 SD
  • CodeineAgonist152 nMToll et al. 1998
    Assay
    guinea-pig brain membranes, [3H]DAMGO competition
    Shown value from
    Toll et al. 1998, Table 5
    Error
    ± 33 SD

Rat

8 measurements
  • BuprenorphineAgonist0.08 nMHuang et al. 2001
    Assay
    recombinant rat MOR in CHO membranes, [3H]diprenorphine competition
    Shown value from
    Huang et al. 2001, Table 1
    Error
    ± 0.02 SEM, n = 4
  • OxymorphoneAgonist0.97 nMBen Haddou et al. 2014
    Assay
    native rat brain membranes, [3H]DAMGO competition
    Shown value from
    Ben Haddou et al. 2014, Table 1
    Error
    ± 0.05 SEM
  • MorphineAgonist6.5 nMBen Haddou et al. 2014 · 2 reports
    Assay
    native rat brain membranes, [3H]DAMGO competition
    Shown value from
    Ben Haddou et al. 2014, Table 1
    Range
    2.2–6.5 nM in 2 reports
    Error
    ± 0.74 SEM
    Sources and values behind the range, same assay family
    ReportValueWhere
    Ben Haddou et al. 20146.5 nMTable 1
    Tzschentke et al. 20072.2 nMTable 1
  • OxycodoneAgonist18 nMMonory et al. 1999 · 3 reports
    Assay
    rat brain membranes, displacement of [3H]DAMGO
    Shown value from
    Monory et al. 1999, Table II
    Range
    15–25 nM in 3 reports
  • 3-HO-PCP39 nMItzhak et al. 1981
    Assay
    rat brain homogenate (minus cerebellum), [3H]morphine 1.13 nM, mu site
    Shown value from
    Itzhak et al. 1981, Table 1B
  • TapentadolAgonist96 nMTzschentke et al. 2007
    Assay
    rat opioid receptor binding assay
    Shown value from
    Tzschentke et al. 2007, Table 1
    Error
    ± 9.0 SEM
  • CodeineAgonist1300 nMTzschentke et al. 2007
    Assay
    rat opioid receptor binding assay
    Shown value from
    Tzschentke et al. 2007, Table 1
    Error
    ± 500 SEM
  • Ibogaine2770 nMCodd 1995 · 2 reports
    Assay
    rat brain membranes, [3H]naloxone displacement in Tris buffer, one-site fit
    Shown value from
    Codd 1995, Table II
    Range
    2770–4460 nM in 2 reports
    Error
    ± 467 SD, n = 3

Unspecified

1 measurement
  • Mitragyninesource not traced204 nMLydecker et al. 2016
    Assay
    MOR opioid receptor binding, quoted in a review table (original assay not restated)
    Shown value from
    Lydecker et al. 2016, Table 1

Functional potency (EC₅₀)

8 substances, 10 displayed values. Strongest first within each organism. Emax is shown where the paper reports it. Efficacy depends on the assay and its reference agonist.

Human

8 measurements
  • BuprenorphineAgonistunresolved2.3 nMToll et al. 1998 · 2 reports
    Assay
    human MOR-CHO cell membranes, [35S]GTPgammaS binding
    Shown value from
    Toll et al. 1998, Table 7
    Range
    2.3–16 nM in 2 reports
    Error
    ± 1.7 SD
    Emax
    66.0 ± 36.0%

    Reported values disagree and no value is established. 2 reports in all, 2.3–16 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Toll et al. 19982.3 nMTable 7
    Obeng et al. 202116 nMTable 3
  • OxymorphoneAgonistdepends on assay4.4 nMBen Haddou et al. 2014
    Assay
    CHO cells expressing human opioid receptor, [35S]GTPγS functional assay
    Shown value from
    Ben Haddou et al. 2014, Table 2
    Error
    ± 0.76 SEM
    Emax
    98.0 ± 1.0%

    Values depend on the assay, species or conditions, and each is valid only for its own. 2 reports in all, 4.4–44 nM.

  • MethadoneAgonist27 nMToll et al. 1998
    Assay
    human MOR-CHO cell membranes, [35S]GTPgammaS binding
    Shown value from
    Toll et al. 1998, Table 7
    Error
    ± 14 SD
    Emax
    116.0 ± 20.0%
  • FentanylAgonistunresolved28 nMObeng et al. 2021 · 4 reports
    Assay
    CHO cells expressing human MOR, [35S]GTPγS binding
    Shown value from
    Obeng et al. 2021, Table 3
    Range
    8.1–110 nM in 4 reports
    Emax
    110.0%

    Reported values disagree and no value is established. 5 reports in all, 8.1–110 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Gillen et al. 2000110 nMTable 2
    Toll et al. 19988.1 nMTable 7
    Obeng et al. 202128 nMTable 3
    Schmid et al. 201743 nMTable 1
  • MorphineAgonistunresolved34 nMBen Haddou et al. 2014 · 6 reports
    Assay
    CHO cells expressing human opioid receptor, [35S]GTPγS functional assay
    Shown value from
    Ben Haddou et al. 2014, Table 2
    Range
    16–125 nM in 6 reports
    Error
    ± 5.1 SEM
    Emax
    89.0 ± 17.0%

    Reported values disagree and no value is established. 8 reports in all, 16–372 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Ben Haddou et al. 201434 nMTable 2
    Tzschentke et al. 200722 nMResults / Fig. 3
    Gillen et al. 2000118 nMTable 2
    Toll et al. 199816 nMTable 7
    Obeng et al. 2021125 nMTable 3
    Schmid et al. 201764 nMTable 1
  • 7-HydroxymitragynineAgonist43 nMObeng et al. 2021
    Assay
    CHO cells expressing human MOR, [35S]GTPγS binding
    Shown value from
    Obeng et al. 2021, Table 3
    Emax
    41.3%
  • OxycodoneAgonist343 nMLalovic et al. 2006
    Assay
    human MOR1 membranes, [35S]GTPgammaS binding
    Shown value from
    Lalovic et al. 2006, Table I
    Error
    ± 7.9 SD, n = 2
  • TapentadolAgonistrange incl. untraced670 nMTzschentke et al. 2007 · 2 reports
    Assay
    recombinant human MOR, [35S]GTPγS functional assay
    Shown value from
    Tzschentke et al. 2007, Results / Fig. 3
    Error
    ± 150 SEM
    Emax
    88.0%
    Sources and values behind the range, same assay family
    ReportValueWhere
    Tzschentke et al. 2007670 nMResults / Fig. 3
    Roulet et al. 2021670 nMTable 1

Mouse

1 measurement

Rat

1 measurement
  • BuprenorphineAgonist0.08 nMHuang et al. 2001
    Assay
    recombinant rat MOR in CHO membranes, [35S]GTPgammaS functional assay
    Shown value from
    Huang et al. 2001, Table 2
    Error
    ± 0.01 SEM
    Emax
    38.0 ± 8.0%

Also reported to act here

Substances reported to act here, without a displayed value.

Values are published numbers in nM per organism. Different assays, species and receptor preparations are not directly interchangeable, and a value does not establish clinical potency or safety.